CytoMed Therapeutics: mDR reports 9.984% stake

The reported 9.984% uses 11,934,908 shares issued and outstanding as of June 30, 2026; the ownership history includes subscriptions, a loan conversion and sales.

Rhea-AI Filing Summary

For CytoMed Therapeutics Ltd, mDR LTD reported beneficial ownership of 1,191,523 ordinary shares, or 9.984% of the class. mDR LTD reported sole voting and dispositive power over those shares, with zero shared voting and dispositive power. The percentage is based on 11,934,908 issuer shares issued and outstanding as of June 30, 2026.

The reported holdings are based on 747,414 shares acquired through subscriptions between 2021 and 2022 and 589,509 shares issued upon conversion of a convertible loan in April 2023. mDR LTD also reported 145,400 shares sold between December 16, 2024 and October 12, 2026.

Key Figures

Beneficial ownership: 1,191,523 shares Percent of class: 9.984% Shares issued and outstanding: 11,934,908 shares +5 more

8 metrics

Beneficial ownership 1,191,523 shares mDR LTD's reported position

Percent of class 9.984% mDR LTD's reported beneficial ownership

Shares issued and outstanding 11,934,908 shares As of June 30, 2026; basis for the reported ownership percentage

Shares acquired through subscription 747,414 shares Between 2021 and 2022

Shares issued upon loan conversion 589,509 shares April 2023

Shares sold 145,400 shares Between December 16, 2024 and October 12, 2026

Convertible Loan principal Approximately $1,118,735.08 Principal amount

Conversion price per share Approximately $1.89774 per share Price for the 589,509 shares issued upon conversion

Key Terms

beneficially owned, Sole Voting Power, Sole Dispositive Power, Convertible Loan

4 terms

beneficially owned financial

"Amount beneficially owned: 1,191,523"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

Sole Voting Power financial

"Sole Voting Power 1,191,523.00"

Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.

Sole Dispositive Power financial

"Sole Dispositive Power 1,191,523.00"

Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

Convertible Loan financial

"conversion in April 2023 of convertible loan"

A convertible loan is money lent to a company that can later be changed into shares instead of being repaid in cash. For investors it combines the safety of a loan—priority for repayment if things go wrong—with the potential upside of owning part of the company if its value rises; think of it as lending money that can be swapped for a slice of the company pie under pre-agreed terms. It matters because it affects returns and how much ownership existing shareholders will have.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many GDTC shares did mDR LTD report owning?

mDR LTD reported beneficial ownership of 1,191,523 CytoMed ordinary shares, equal to 9.984% of the class. It reported sole voting and dispositive power over those shares.

What were the terms of mDR LTD’s convertible loan conversion into GDTC shares?

The convertible loan had a principal amount of approximately $1,118,735.08, and 589,509 shares were issued upon its conversion in April 2023 at approximately $1.89774 per share. The stated consideration and per-share price use an exchange rate of 1.3408 Singapore dollars to one United States dollar.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/23/2026 - 09:00 AM EDT Accepted by SEC EDGAR 10/23/2026 - 09:00 AM EDT Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 3)

CytoMed Therapeutics Ltd

(Name of Issuer)

Ordinary Shares, no par value per share

(Title of Class of Securities)

Y1R80M106

(CUSIP Number)

10/12/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): Y1R80M106

1

Names of Reporting Persons

mDR LTD

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

SINGAPORE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 1,191,523.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 1,191,523.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,191,523.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.984 %

12

Type of Reporting Person (See Instructions)

CO

Comment for Type of Reporting Person: (1) This total is based on (i) 747,414 Ordinary Shares acquired by mDR Limited through subscription of the Issuer's Ordinary Shares between 2021 and 2022 for total consideration of approximately $1,185,449; (ii) 589,509 Ordinary Shares pursuant to the conversion in April 2023 of convertible loan (the "Convertible Loan") issued under the convertible loan agreement, dated December 10, 2019, by and between mDR Limited and CytoMed Therapeutics Pte. Ltd., as amended by supplemental agreements dated December 31, 2021, January 3, 2022 and January 3, 2023 (the "Convertible Loan Agreement"); and (iii) 145,400 Ordinary Shares sold between December 16, 2024 and October 12, 2026. The principal amount of the Convertible Loan was approximately $1,118,735.08 and the 589,509 Ordinary Shares were issued at approximately $1.89774 per share pursuant to the terms of the Convertible Loan. The foregoing consideration amount and price per share are based on an exchange rate of 1.3408 Singapore dollars to one United States dollar. (2) Based on 11,934,908 shares of the Issuer's common stock issued and outstanding as of June 30, 2026, as disclosed on the Issuer's Unaudited Interim Condensed Consolidated Financial Statements for the Six Months Ended June 30, 2026, included as Exhibit 99.1 to the Issuer's Form 6-K filed with the Securities and Exchange Commission (the "Commission") on September 30, 2026.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: CytoMed Therapeutics Ltd
(b)	Address of issuer's principal executive offices: #08-22 One Commonwealth 1 Commonwealth Lane Singapore U0 149544
Item 2.
(a)	Name of person filing: mDR LTD (the "Reporting Person")
(b)	Address or principal business office or, if none, residence: 53 Ubi Crescent, Singapore 408594
(c)	Citizenship: Republic of Singapore
(d)	Title of class of securities: Ordinary Shares, no par value per share
(e)	CUSIP No.: Y1R80M106
Item 4.	Ownership
(a)	Amount beneficially owned: 1,191,523
(b)	Percent of class: 9.984%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 1,191,523
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 1,191,523
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.	Certifications:
	Not Applicable

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

mDR LTD

Signature:	/s/ Edward Lee Ewe Ming
Name/Title:	Executive Chairman
Date:	10/23/2026